BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
26.49
+0.28 (1.07%)
Dec 20, 2024, 4:00 PM EST - Market closed
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for BridgeBio Pharma stock have an average target of 47.92, with a low estimate of 37 and a high estimate of 70. The average target predicts an increase of 80.90% from the current stock price of 26.49.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BBIO stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 3 | 4 | 6 | 6 | 6 |
| Hold | 2 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 9 | 10 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $49 | Strong Buy | Reiterates | $49 | +84.98% | Dec 16, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $45 → $48 | Buy | Maintains | $45 → $48 | +81.20% | Nov 25, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $42 → $45 | Strong Buy | Maintains | $42 → $45 | +69.88% | Nov 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $43 → $49 | Strong Buy | Maintains | $43 → $49 | +84.98% | Nov 25, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $44 → $45 | Buy | Maintains | $44 → $45 | +69.88% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
255.69M
from 9.30M
Increased by 2,648.47%
Revenue Next Year
190.56M
from 255.69M
Decreased by -25.47%
EPS This Year
-2.36
from -3.95
EPS Next Year
-3.63
from -2.36
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 759.9M | 360.2M | 645.9M | |||
| Avg | 255.7M | 190.6M | 402.0M | |||
| Low | 206.9M | 59.8M | 218.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 8,068.0% | 40.9% | 238.9% | |||
| Avg | 2,648.5% | -25.5% | 111.0% | |||
| Low | 2,124.0% | -76.6% | 14.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.85 | -2.55 | -1.69 | |||
| Avg | -2.36 | -3.63 | -2.78 | |||
| Low | -3.37 | -4.41 | -3.75 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.